Cargando…

Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria

PURPOSE: Novel therapy has dramatically changed the outcome of patients with myeloma. Current National Comprehensive Cancer Network guidelines give bortezomib-based combinations a central role in the management of multiple myeloma (MM). The aim of this survey is to assess the use of bortezomib for t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korubo, Kaladada I., Madu, Anazoeze J., Okoye, Helen C., Nwogoh, Benedict
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2017
Materias:	Original Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180763/ https://www.ncbi.nlm.nih.gov/pubmed/30241144 http://dx.doi.org/10.1200/JGO.17.00033

Ejemplares similares

Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria
por: Madu, Anazoeze Jude, et al.
Publicado: (2019)

Perception to Hydroxyurea Therapy in Patients with Sickle Cell Disease: Report from 3 Centers
por: Korubo, Kaladada I., et al.
Publicado: (2021)

Pattern and prevelence of alloimmunization in multiply transfused patients with sickle cell disease in Nigeria
por: Kangiwa, Umar, et al.
Publicado: (2015)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Multiple myeloma in Nigeria: a multi-centre epidemiological and biomedical study
por: Nnonyelum, Odunukwe Nkiruka, et al.
Publicado: (2015)

Identifying Educational Needs and Practice Gaps of European Hematologists and Hematology Nurses in the Treatment and Management of Multiple Myeloma
por: Murray, Suzanne, et al.
Publicado: (2018)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Chronic Lymphocytic Leukemia: Prognostic Factors at Presentation in a Resource-Limited Center
por: Korubo, Kaladada Ibitrokoemi, et al.
Publicado: (2021)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2017)

Gaucher Disease for Hematologists
por: Özdemir, Gül Nihal, et al.
Publicado: (2022)

PB2351: ANXIETY AT THE HEMATOLOGIST
por: Trojan, S., et al.
Publicado: (2022)

Health Status of Persons with Hemophilia: A Pilot Survey from a Resource-Constrained Country
por: Okoye, Helen C., et al.
Publicado: (2019)

Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
por: Painuly, Utkarsh, et al.
Publicado: (2013)

MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment
por: Gu, Chunyan, et al.
Publicado: (2015)

Blood Donation in Nigeria: Standard of the Donated Blood
por: Benedict, Nwogoh, et al.
Publicado: (2012)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Bortezomib a Safe Treatment for Patients with Multiple Myeloma and Cystic Fibrosis
por: Gentilini, Fabiana, et al.
Publicado: (2012)

The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma
por: Yi, Yang-Seon, et al.
Publicado: (2010)

Effect of bortezomib on the treatment of multiple myeloma: a systematic review protocol
por: Cantadori, Lucas Oliveira, et al.
Publicado: (2022)

Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives
por: Sanz-Solas, Antonio, et al.
Publicado: (2023)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
por: Zhou, Pan, et al.
Publicado: (2022)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Tumor lysis syndrome in multiple myeloma treated with bortezomib
por: Dhanraj, K. M., et al.
Publicado: (2014)

A feline case of multiple myeloma treated with bortezomib
por: Tani, Hiroyuki, et al.
Publicado: (2022)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
por: Han, Joseph, et al.
Publicado: (2023)

Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells
por: Starheim, K K, et al.
Publicado: (2016)

Parental Perception of Childhood Anaemia and Efficiency of Instrument Assisted Pallor Detection among Mothers in Southeast Nigeria: A Field Validation Study
por: Ughasoro, Maduka Donatus, et al.
Publicado: (2019)

The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients
por: Bacci, Christian, et al.
Publicado: (2021)

Behavioral Patterns in Breaking Bad News Communication: An Ethnographic Study with Hematologists
por: Artioli, Giovanna, et al.
Publicado: (2022)

Knowledge, Attitude, and Practice of Voluntary Blood Donation among Healthcare Workers at the University of Benin Teaching Hospital, Benin City, Nigeria
por: Nwogoh, Benedict, et al.
Publicado: (2013)

Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma
por: Salmenniemi, Urpu, et al.
Publicado: (2012)

Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells
por: Song, In-Sung, et al.
Publicado: (2013)

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
por: Mateos, Maria V., et al.
Publicado: (2021)

Shoulder pain: a hematologist’s perspective
por: Jain, Ankur, et al.
Publicado: (2016)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib
por: Wu, Cuicui
Publicado: (2022)

Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
por: Lee, Won-Seop, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_hskmcri87td7dcsel5og4j7pq6